All Comments by

  1. Paul Aisen on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
  2. Bart De Strooper on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
  3. Stefan Lichtenthaler on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
  4. William Goure on CTAD: Solanezumab Seen to Nudge AD Ever so Slightly
  5. Ian Clark on After Solanezumab: Where Should Alzheimer’s Research Go?
  6. Oskar Hansson on Touchdown for NfL: Blood Test Tells Parkinson's from Related Disorders
  7. Andy Shih on Pericytes Don’t Go With the Flow—They Change It
  8. Lei Feng on Being Bilingual Buffers Against Alzheimer’s by Improving Connectivity
  9. Pedro Rosa-Neto on Do Astrocytes Blur the PET Signal for ‘Neuronal’ Activity?
  10. Anusha Mishra on Pericytes Don’t Go With the Flow—They Change It
  11. Michael Lardelli on Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase.
  12. Marcel Verbeek on Touchdown for NfL: Blood Test Tells Parkinson's from Related Disorders
  13. Scott Small and Gregory A. Petsko on Lindquist Leaves Behind Parkinson’s Interactome as Her Parting Gift
  14. Kassandra Kisler, Amy Nelson and Berislav Zlokovic on Pericytes Don’t Go With the Flow—They Change It
  15. Michele Vendruscolo on Building ProteomeTools based on a complete synthetic human proteome.